We are pleased to announce that PhalconBio has secured £1 million grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy) to propel its lead anti-Pseudomonas program.

‍

PACE is one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery. It was founded in 2023 by LifeArc, Medicines Discovery Catapult and Innovate UK with a £30 million programme of funding and support to be deployed over five years. PACE helps to fast-track the most promising antimicrobial innovations by providing essential resources and support, maximizing the chances of success in the fight against antimicrobial resistance (AMR).

‍

PACE seeks to fund and support global AMR innovators with the best science. Projects in the PACE portfolio receive funding and additional support, including R&D advice and access to a UK network of delivery partners, to drive the projects forward for onward investment and ultimately closer to clinical impact.

‍

PhalconBio, a Swiss biotech company, is committed to delivering ground-breaking precision medicines to address critical challenges in AMR and beyond. By leveraging its proprietary engineered-phage platform, the company is tackling multidrug-resistant infections with innovative, phage-based therapeutic solutions.  

‍

PACE has today announced PhalconBio as one of the awardees of its £10m antimicrobial therapeutics funding call. Through funding and support, PACE will help PhalconBio in the development of engineered phage therapies targeting lower respiratory tract infections caused by multidrug-resistant Pseudomonas aeruginosa.

‍

Dr. Beverley Isherwood, PACE Programme Director, said: “We are delighted to have PhalconBio join the first group of PACE-supported projects with their innovative platform to develop precision antimicrobials. Through a collaborative effort, PACE will assist PhalconBio in generating the key data packages needed to position the project for future investment, funding, and advancement.”

‍

Dr. Samuel Kilcher, Founder of PhalconBio, said: “AMR remains a significant global challenge, and we are deeply appreciative of PACE's support and recognition of our platform technology. This collaboration allows us to accelerate our efforts to combat drug resistance and provide life-changing therapies for patients in need.”

‍

‍

‍